|
|
CalciMedica (USA) is dedicated to the discovery and development of novel small molecule drugs for the treatment of autoimmune and inflammatory diseases. A significant focus of the company’s drug discovery strategy is based on the specific inhibition of calcium release-activated calcium (CRAC) channels. http://www.calcimedica.com |
![]() |
CoNCERT Pharmaceuticals, Inc (USA) creates new drugs by using precision deuterium chemistry to modify the pharmacology of existing and new small molecule compounds to create a treatment benefit. http://www.concertpharma.com |
![]() |
CyDex (USA) develops and commercializes specialty
pharmaceutical products based on drug delivery and
formulation technologies.
http://www.cydexinc.com |
![]() |
Locus Pharmaceuticals, Inc. (USA) applies its core fragment-based, computational drug design technology with its capabilities in medicinal chemistry, crystallography and biology to create small molecule product. The company has a portfolio of emerging candidates in development for cancer and inflammation.
http://www.locuspharma.com |
![]() |
Novalar Pharmaceuticals, Inc.(USA) is a specialty pharmaceutical company. Lead asset NV-101, for the reversal of numbness associated with local dental anesthesia, has completed Phase III trials. An NDA was filed in 2007.
http://www.novalarpharm.com |
![]() |
Nucleonics, Inc. (USA) is a drug discovery and development company that
is using proprietary RNAi technologies for the treatment of infectious
and other diseases.
http://www.nucleonicsinc.com |
![]() |
Protez Pharmaceuticals (USA) discovers and develops new anti-microbials
to combat the growing problem of drug resistance, as well as agents
that improve the efficacy of current antibiotics.
http://www.protez.com |
![]() |
Rib-X Pharmaceuticals (USA) is developing novel classes of anti-microbials to address
unmet needs in resistant community and hospital-acquired infections
using structure-based drug design and its proprietary knowledge of the
crystal structure of the 50S subunit of the ribosome and other
important targets.
http://www.rib-x.com |
![]() |
Scynexis, Inc. (USA) offers drug discovery and development services to
biotech and pharmaceutical companies through a suite of research,
development and products.
http://www.scynexis.com |
![]() |
Trinity Biosystems (USA) is using its novel platform of oral and nasal delivery to develop proteins and peptide therapeutics.
http://www.trinitybiosystems.com |
![]() |
Zelos Therapeutics (USA) is developing new treatments for
osteoporosis and other indications based on breakthrough discoveries in
parathyroid hormone research. Lead candidate Ostabolin C is in Phase II
trials.
http://www.zelostherapeutics.com |